Facts about MSS FH1536™

 

1. What is Molecular Screening Services (MSS) for FH1536™ and what does the test result tell me?

  • If you are a healthy person, the test evaluates your risk of developing hypercholesterolemia
  • If you have hypercholesterolemia, the test determines whether you harbour the risk alleles for FH thereby diagnoses whether you are definite FH or not.

 

MSS FH1536™ screens for 1536 polymorphisms selected from more than 70 genes with emphasis given to the 3 main genes namely: LDLR gene, ApoB (ApolipoproteinB) gene and PCSK9 (Proprotein convertase subtisilin/kexin type 9) gene. MSS FH1536™includes both molecular and clinical examination. Molecular examination involves the scanning of your DNA, in search of related polymorphisms inherited from your parents. Clinical examination associates your lifestyle choices, family history and medical history to FH risk. The combined clinico-molecular analysis thus provides a more thorough and comprehensive risk assessment.

 

 

2. What procedure is involved?

A small sample of blood (about 3-8.5ml) will be collected and clinical information will be recorded. The procedure is non-invasive. DNA will be extracted from the blood sample and subjected to High Density Microarray Technology based SNP genotyping. A blood test is independently done to evaluate the Lipid profile. Clinical information will be examined by our panel of specialists.

 

 

3. Who should take this test?

  • Healthy individuals
  • Individuals with hypercholesterolemia
  • Relatives / children of FH patients

Any individual who has suffered from Familial Hypercholesterolemia should consider ordering the test for their offspring, and blood relatives for comparative study, in order to ascertain if the same FH-causing genetic markers have been passed on or shared by your loved ones.

 

 

4. How frequent do I need to go for Screening?

The molecular test result represents one’s genetic profile at that time of testing. The probability of your DNA getting mutations at the exact locations of risk-associated SNPs is low within a short span of time. However, your clinician may advise you on the need for future screening if there is an updated test panel

 

 

5. What are the limitations of the test?

The test panel captures the genetic variations which are documented based on the current research status. As scientific research and development progress, more genetic variations will be identified. Our research scientists will continuously upgrade the panel as more discoveries are made.

 

 

6. How is FH currently treated?

FH is treated using diet management, medication and, in some cases, LDL-apheresis in order to lower the LDL cholesterol in the blood. A diet high in fiber and low in fat, saturated fat and cholesterol can help lower these levels. Your Physician may also recommend weight lose regime  begin with exercise program. If diet and exercise are not enough to lower cholesterol levels, your Physician may prescribe Statin medication. To prevent hypercholesterolemia, people should adopt a healthy diet, exercise regularly, quit smoking, maintain a healthy body weight and  most importantly have cholesterol levels checked regularly by your Physician. People who have a family history of early heart attacks should be monitored regularly. FH1536™ test which assess a person's molecular condition enables early detection of the disease, even before the clinical symptons appears, therefore allows early intervention.